察爾斯大夫 美麗殿堂 Dr. Charles Meridien Palace

星星美人千頌伊完美裸妝有撇步

作者：【記者蘇湘雲／台北報導】 | 台灣新生報 – 2014年3月13日

受到當紅韓劇《來自星星的你》影響，劇中女主角千頌伊的完美臉蛋成為眾多女性羨慕的對象，劇中多以裸妝呈現的千女神絲毫看不出比男主角大六歲。

整形外科醫師鄭紹隆表示，女性若要看起來較年輕，關鍵在於飽滿的蘋果肌與下半臉緊緻線條，想要在短時間擁有像全智賢一樣飽滿緊緻的愛心臉，可以考慮透過玻尿酸或自體脂肪填補蘋果肌，再加上肉毒桿菌注射修飾或下半臉拉皮手術，就可以達到緊緻飽滿愛心臉效果。

蘋果肌飽滿常給予人好氣色的感覺，就算只上淡妝或裸妝，也能呈現出年輕朝氣之感，鄭紹隆醫師分析，若想有效達到蘋果肌飽滿效果，自體脂肪填補是非常直接、有效的方式。

傳統自體脂肪填補由於脂肪純化技術不純熟，往往需要多次注射才有好結果，且脂肪存活率並不高。但現在醫療發達，只要選擇專業醫師，透過專業操作，多數只要一次手術就能達到飽滿效果，脂肪存活率也大大提升。

而對於在意修復期的人，則可以選擇玻尿酸注射填補，微整的好處是效果立現，也幾乎不需要回診追蹤，加上隨時可以視情況追加劑量，受到許多忙碌上班族青睞。

對於下半臉線條的修飾，需要先由專業醫師評估下半臉的狀態，來選擇適合塑型方式，例如兩頰旁肥厚的咀嚼肌，可透過注射肉毒桿菌來阻斷神經傳遞，讓肥厚的肌肉變小，達到修飾寬大國字臉目的。

此外，注射肉毒桿菌也能提拉臉頰到脖子線條，但對於兩頰皮膚組織鬆弛或出現嘴邊肉等老化現象的人，則應利用下半臉拉皮來提拉下垂組織，才會有明顯改善效果。

若選擇像玻尿酸注射、肉毒桿菌這種微整方式雕塑，幾乎不太需要恢復期，但要注意的是效果並非永久，需要定期注射才能維持一定的效果，由專業醫師操作，可以幫助減少效果不彰、注射位置不正確等問題。

相對的，若是接受像自體脂肪補臉、拉皮等侵入性手術療程的人，則應配合醫師指示定期回診追蹤檢查，並按時冰敷、溫敷，以及服用消炎藥物，才能避免術後感染等風險，達到良好術後結果。

鄭紹隆醫師提醒，無論選擇哪種療程，都應慎選專業醫師，多聽、多問、多討論，了解自己本身的臉部條件，並醫師詳細溝通心中的期待，避免因為貪便宜而增加出血、感染等治療併發症風險，因小失大。

別惡整！小心「水微晶」變「水管鼻」

華視 – 2014年3月13日

愛美的女性要注意了，在台北有少女接受水微晶隆鼻，沒想到後來鼻樑變得像水管一樣又粗又直，非常不自然，醫師提醒現在能施打的填充物很多，但水微晶、玻尿酸比較適合打在蘋果肌或淚溝上，而且並不是打越多越好。

ANGELA BABY深邃眼睛，高挺鼻樑，完美的五官，讓不少女人都想變成她，尤其韓國女星泫雅的鼻子，被韓國醫美視為是最佳黃金比例，在台北就有少女也想擁有高挺鼻樑，用水微晶隆鼻，沒想到，手術後的鼻子，就像一根又粗又直的水管，黏在鼻子上。

使用的填充物有差，像是微晶瓷因為含有鈣、礦物質等等，質地較硬，比較適合用在鼻樑下巴，但如果是要填淚溝或是蘋果肌，玻尿酸和水微晶會比較適合，但別以為微整型就沒有風險，鼻頭血管因為被填充物阻塞，發紅發腫最後組織壞死，甚至會導致失明。提醒您做任何手術前，都最好審慎評估，以免愛美不成變醜。

抄論文還直接剪貼「STAP細胞」日美女博士小保方晴子學位不保

作者：黃菁菁╱東京12日電 | 中時電子報 – 2014年3月13日上午5:56

中國時報【黃菁菁╱東京12日電】

因發表新的萬能細胞「STAP細胞」論文，而紅極一時的日本美女研究員小保方晴子，繼遭到質疑論文不實之外，連她過去所撰博士論文的參考文獻，都被懷疑可能抄襲自台灣醫學研究人員們在醫學期刊發表的論文，以及美國國家衛生研究院的文章。若查證屬實，小保方恐將因而被取消博士學位。

日本理化學研究所日前召開記者會宣布，以小保方等人為首的研究小組，研發出「STAP細胞」。後來不少研究學者質疑，按照該論文內容進行實驗都無法製造出「STAP細胞」，且小保方在論文中使用的部分照片，疑似沿用她過去的博士論文相片，並非研究萬能細胞時所拍的相片。

《朝日新聞》12日報導，小保方2011年2月，在早稻田大學提出的「從動物體內找出萬能性的幹細胞」之英文博士論文，參考文獻名單內有38件文獻，酷似台灣的醫院研究團隊發表的論文。

《朝日新聞》指出，台灣研究論文的文獻名單裡共有53件文獻，小保方的論文文獻名單中，1至38件幾乎內容都一致。小保方的論文有部分出現亂碼，有可能是直接剪貼自其他論文。

Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.

Wildes TM1, Augustin KM, Sempek D, Zhang QJ, Vij R, Dipersio JF, Devine SM.

Biol Blood Marrow Transplant. 2008 Jul;14(7):840-6.

doi: 10.1016/j.bbmt.2008.05.002.

Abstract

High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation is a widely applied treatment for advanced non-Hodgkin lymphoma (NHL), but few studies have analyzed the tolerability and outcomes in older patients compared with younger patients treated in a homogeneous manner. We retrospectively reviewed 152 consecutive patients who underwent autologous stem cell transplantation (ASCT) following BEAM conditioning (carmustine, etoposide, cytarabine, and melphalan) for NHL from January 2000 through August 2004 at our institution. We compared 59 patients age > or =60 years and 93 patients age <60 years. Supportive care was identical for all patients. The frequency of comorbidities was similar between both groups. CD34+ cell doses, days to neutrophil recovery, and days to platelet count >20,000/mm3 were similar in younger and older patients, although days to platelet count >50,000/mm3 were longer in the older patients (median 30.0 days versus 22.5 days, P = .01). Patients over the age of 60 were more likely to develop grade III/IV mucositis than their younger counterparts (37.7% versus17.4%, P = .0063). Otherwise, the frequency of other grade III/IV toxicities were similar between younger and older patients. Treatment-related mortality (TRM) was similar between older and younger patients (8.5% versus 5.4%, P = .45). Although age was not associated with TRM, the Charlson Comorbidity Index Score was significantly correlated with TRM (P = .03). Median disease-free survival was similar between older and younger patients (21.8 months versus 29.9 months, P = .93), as was overall survival (OS) (47.7 months versus 62.5 months, P = .20). After controlling for age, the Charlson Comorbidity Index Score influenced OS [P = .013]. Overall, our cohort of patients with NHL over the age of 60 who underwent ASCT following BEAM conditioning experienced toxicities and survival similar to their younger counterparts. Comorbidities significantly influenced TRM and OS in this retrospective cohort. Future study should focus on improving tolerability of conditioning and careful prospective evaluation of comorbidities and their association with outcomes.

PMID: 18541205 [PubMed - indexed for MEDLINE]

Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation

Mahmood S Choudhery12, Michael Badowski2, Angela Muise2, John Pierce3 and David T Harris2*

* Corresponding author : David T Harris davidh@email.arizona.edu

Author Affiliations

1 Advanced Centre of Research in Biomedical Sciences, King Edward Medical University, Lahore, Pakistan

2 Department of Immunobiology, College of Medicine, The University of Arizona, PO Box 245221, 85724, Tucson, AZ, USA

3 Aesthetic Surgery of Tucson, Tucson, AZ, USA

Journal of Translational Medicine 2014, 12:8

doi:10.1186/1479-5876-12-8

The electronic version of this article is the complete one and can be found online at : http://www.translational-medicine.com/content/12/1/8

Received : 23 September 2013

Accepted : 3 December 2013

Published : 7 January 2014

© 2014 Choudhery et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

Background

Human adipose tissue is an ideal autologous source of mesenchymal stem cells (MSCs) for various regenerative medicine and tissue engineering strategies. Aged patients are one of the primary target populations for many promising applications. It has long been known that advanced age is negatively correlated with an organism’s reparative and regenerative potential, but little and conflicting information is available about the effects of age on the quality of human adipose tissue derived MSCs (hAT-MSCs).

Methods

To study the influence of age, the expansion and in vitro differentiation potential of hAT-MSCs from young (<30 years), adult (35-50 years) and aged (>60 years) individuals were investigated. MSCs were characterized for expression of the genes p16INK4a and p21 along with measurements of population doublings (PD), superoxide dismutase (SOD) activity, cellular senescence and differentiation potential.

Results

Aged MSCs displayed senescent features when compared with cells isolated from young donors, concomitant with reduced viability and proliferation. These features were also associated with significantly reduced differentiation potential in aged MSCs compared to young MSCs.

Conclusions

In conclusion, advancing age negatively impacts stem cell function and such age related alterations may be detrimental for successful stem cell therapies.

Keywords : Adipose tissue; Mesenchymal stem cells; Donor age; Regenerative potential; Growth kinetics; In vitro differentiation potential

Fat Stem Cells are not affected by Weight or Age

Mojallal et al.

Aesthetic Plast Surg.

Fat represents a potent source of autologous stem cells. Historically, the majority of research using autologous stem cells involved stem cells collected from the bone marrow. This source is associated with a painful extraction procedure and relatively low concentrations of mesenchymal stem cells. In contract, mini-liposuctions represent a less invasive extraction approach. Additionally, adipose tissue has been shown to contain substantially higher number of mesenchymal stem cells as well as hematopoietic stem cells and endothelial progenitor cells.

The use of fat derived stem cells has grown exponentially in recent years for numerous indications. Perhaps the largest data set for fat derived stem cells is possessed by Dr. Bob Harman from Vet Stem, who has treated a total of more than 10,000 large animals with this procedure. The Cellmedicine clinic has had an excellent track record of success using autologous fat for treatment of multiple sclerosis having treated more than 200 patients.

One of the major limiting factors of stem cell therapy using your own stem cells (autologous) is that the potency and number of stem cells is believed to decrease with age and disease. These studies, however, have been performed primarily from bone marrow sources of stem cells. Any hematologist will tell you that with age the bone marrow becomes drier and possesses less cells. Studies have shown that bone marrow stem cells from patients with Diabetes or from Obese patients have less activity as compared to age matched controls. There has been some thought that the stem cells in the adipose tissue are protected from age and disease. A current study－Mojallal et al. Influence of Age and Body Mass Index on the Yield and Proliferation Capacity of Adipose-Derived Stem Cells. Aesthetic Plast Surg. 2011 May 26－from the Service de Chirurgie Plastique, Reconstructrice et Esthétique in Lyon France sought to address this. The investigators assessed 42 women who were divided into two groups: age ≤ 40 or >40 and BMI ≤ 25 or >25. Fat tissue was harvested via manual lipoaspiration from the abdominal region. After centrifugation, 100 ml of lipoaspirate was sent to the laboratory for isolation and cultivation of ASCs. The investigators found that average cell yield was 0.380 × 10(6)/ml. Cell yield and proliferation capacity did not show statistically significant correlation to the Age and BMI of patients, nor was there a statistically significant difference between cell yield and proliferation capacity between the different groups.

The study looked at some very basic parameters : cell number, viability and proliferative ability. It may be that adipose stem cells may exhibit differences in immune modulatory potential or differentiation potential between donors. This was not assessed. Additionally, the adipose derived cells were not assessed between donors suffering from different conditions. Despite these shortcomings, the data appears to support the hypothesis that adipose derived stem cells may have some advantages as compared to bone marrow stem cells, at least for autologous uses.

Chondrogenic Potential of Human Adult Mesenchymal Stem Cells Is Independent of Age or Osteoarthritis Etiology

Alwin Scharstuhl1,2, Bernhard Schewe3, Karin Benz1, Christoph Gaissmaier3,

Hans-Jörg Bühring4, Reinout Stoop Ph.D.1,*

Article first published online: 13 SEP 2007

DOI: 10.1634/stemcells.2007-0300

Copyright © 2007 AlphaMed Press

STEM CELLS Volume 25, Issue 12, pages 3244–3251, December 2007

Keywords :

Mesenchymal stem cells ; Differentiation ; Isolation ; Chondrogenic differentiation ; Age-related ; Etiology

Abstract

Osteoarthritis (OA) is a multifactorial disease strongly correlated with history of joint trauma, joint dysplasia, and advanced age. Mesenchymal stem cells (MSCs) are promising cells for biological cartilage regeneration. Conflicting data have been published concerning the availability of MSCs from the iliac crest, depending on age and overall physical fitness. Here, we analyzed whether the availability and chondrogenic differentiation capacity of MSCs isolated from the femoral shaft as an alternative source is age- or OA etiology-dependent. MSCs were isolated from the bone marrow (BM) of 98 patients, categorized into three OA-etiology groups (age-related, joint trauma, joint dysplasia) at the time of total hip replacement. All BM samples were characterized for cell yield, proliferation capacity, and phenotype. Chondrogenic differentiation was studied using micromass culture and analyzed by histology, immunohistochemistry, and quantitative reverse transcriptase-polymerase chain reaction. Significant volumes of viable BM (up to 25 ml) could be harvested from the femoral shaft without observing donor-site morbidity, typically containing >107 mononuclear cells per milliliter. No correlation of Age or OA etiology with the number of mononuclear cells in BM, MSC yield, or cell size was found. Proliferative capacity and cellular spectrum of the harvested cells were independent of age and cause of OA. From all tested donors, MSCs could be differentiated into the chondrogenic lineage. We conclude that, irrespective of age and OA etiology, sufficient numbers of MSCs can be isolated and that these cells possess an adequate chondrogenic differentiation potential. Therefore, a therapeutic application of MSCs for cartilage regeneration of OA lesions seems feasible.

生機≠有機　專家教怎麼吃最健康？

作者：華人健康網記者駱慧雯／台北報導 | 華人健康網 – 2014年3月11日

「生機飲食」強調食材的原味，主張生吃、未經高溫烹調。

天然食療的養生風氣盛行，坊間常可看到生機飲食專賣店拿著一杯杯濃稠的鮮綠色果汁，鼓勵民眾試喝，宣稱食材都是新鮮的有機蔬果，不經高溫破壞營養素，可促進健康。不過，「生機飲食」等同於「有機飲食」嗎？真的具有保健的效果嗎？就讓專家來解答。

生機≠有機　健康基礎大不同

中華民國營養師公會全國聯合會理事長蔡玲貞表示，「生機飲食」的主要訴求在於「維持生命力」，強調食材不經繁瑣的處理或烹調程序，最能保留食物本身的營養價值，提供人體活力和生命力所需的養分，因此吃東西時會以糙米取代精緻白米，全麥麵包取代精緻麵粉製品，以蔬果以生吃為原則，不以高溫烹飪或添加人工調味劑。

至於「有機」，各國的定義不同，但共通的精神是，「有機食品」皆需符合仰賴土壤原有的養分自然生產，栽種或生產過程不能使用農藥、化學肥料、黴菌抑制劑、殺蟲劑、抗生素等非天然的產品。而生機飲食常使用有機蔬果當作生吃的食材，原因之一也就在於其不使用人工藥物的「簡單化生產方式」，符合生機飲食的養生概念。

生機飲食藏風險　熟食殺菌較安心

不過，無論是不是有機蔬果，特別是罹患癌症和慢性疾病的人，最好避免趕搭生機飲食的風潮，所有食物最好還是煮熟，至少要用熱水汆燙、沖洗後再吃。

蔡玲貞營養師強調，生機飲食的精髓在於「生食」，但慣行栽種的農作物會有農藥殘留的疑慮，誤食過量恐腸胃不適，損害肝腎功能；而看似天然健康的有機農業，則因允許使用有機肥料，如廚餘堆肥、排泄物做的肥料，裡面可能藏有細菌、黴菌、寄生蟲蟲卵等，農作物未經清洗和烹調就生吃，可能也把病菌吃下肚，恐會引發腸胃不適。

而剛接受化療的癌症病患，或是患有心血管疾病、糖尿病、肝炎等慢性疾病的患者，身體抵抗力差，若遵行生機飲食的生食方式，不小心把病菌吃下肚，所引起的併發症會比一般人來得嚴重，建議無論是否為有機蔬果，熟食還是比生食來得安心。

養生飲食！首選成熟的當季蔬果

此外，如何挑選對的蔬果，也是健康飲食的一大關鍵。每天攝取足量蔬果可降低癌症發生率，但目前還沒有研究證實有機蔬果可防癌，因此民眾不用拘泥於非吃有機不可。

蔡玲貞營養師建議，民眾購買食材時，最好購買當季的蔬果，買回家後放在室外約2至3天，可降低慣行農作物的農藥殘留量，也可讓使用有機堆肥栽種的有機蔬果，持續接受光合作用，減少農作物中的氮、磷和硝酸鹽濃度，讓人吃得更健康。

需注意的是，近來有很多人自己嘗試用有機的方式種植蔬果，營養師提醒最好等到蔬果成熟後再摘，且避免清晨採收，此時因缺乏光照，硝酸鹽含量較高，建議等傍晚再採收較好。

外貌助男往上爬女性卻未必

中央社 – 2014年3月12日

（中央社台北11日電）

新研究指出，外貌能幫助男性在事業上向前邁進，但美麗的女性要往上爬卻面臨一番奮鬥。

英國「每日郵報」（Daily Mail）報導，研究顯示，倘若負責推銷的男性長得帥，投資人比較容易掏錢投資；但美女企業家比起長相較平凡的女性，成功機率並沒有比較大。

所以外表具吸引力到底是幸或不幸？這項研究說，推特共同創辦人杜錫（Jack Dorsey）等帥氣逼人的男性企業家，要往上爬比較容易，但對英國知名內衣品牌Ultimo創辦人莫妮（Michelle Mone）等美女企業家而言，卻沒這麼簡單。

研究結果發表於美國國家科學院學報（PNAS），研究並指出，女性在企業中仍面對不少障礙，因為投資人偏愛男性作簡報。

英國FTSE 100上市公司中僅4家的執行長是女性，美國發展中的創投公司90%則由男性創立或領軍。

哈佛商學院（Harvard Business School）的布魯克斯（Alison Brooks）表示：「我們發現業界持續存在很深的性別鴻溝。」

（譯者：中央社蔡佳伶）

抗凝血劑和舒經活血湯併用　恐抑制凝血

優活健康網 – 2014年3月11日下午6:45

（優活健康網實習記者張瓊之／綜合報導）

近來，民眾對於中醫藥的接受度逐漸增加，且在中西醫結合的優勢下，民眾同時接受中藥及西藥治療的情況愈來愈廣泛，但在兩者併用的情況下，醫師一定要明瞭各自的優缺點，再依照其中一種或合併使用兩種不同的醫療模式，幫患者尋找最有利的醫療方法。

目前常見中西醫合併的病患為慢性病患者，中藥與西藥合用後，所發生的藥物交互作用值得重視，若使用不當，不僅療效降低，還會增加不必要之副作用，甚至造成嚴重的後果，所以無論中醫或是西醫均應重視此一重要議題。

中西醫　臨床上所表現皆不同

罹患心血管疾病的病患常需長期服用西藥抗凝血劑，或是開刀的患者在事前也應該避免服用抗凝血劑，因此如何避免這類病患在不明情況下服用具有抑制凝血作用之中藥，以免產生不良後果，成為現今醫師們最重要的課題。

臨床研究　中西醫併用增加抗凝血作用

中藥複方「疏經活血湯」主功效為疏筋活血，中醫常用於治療筋骨痠痛，尤其是退化性關節炎的患者。

為瞭解複方與西醫抗凝血劑服用後所產生的結果，因而進行研究，以不同濃度中藥複方「疏經活血湯」服用，同時服下西藥抗凝血劑「Warfarin」以瞭解是否會因中西藥合併使用，產生抗凝血的加成作用。

研究結果顯示，中藥「疏經活血湯」併用西藥Warfarin，會增強西藥的抑制凝血作用，因此建議，日後臨床上使用西藥Warfarin的病患，如需使用中藥「疏經活血湯」時應更加謹慎，並須經由中醫師評估後給藥，民眾不要擅自自行購藥服用，以免產生不要之副作用。